IFO50108 MG-63
Cell information
Cell type:general cells (View Pricing Information)
JCRB No. | IFO50108 | Cell Name | MG-63 |
---|---|---|---|
Profile | osteosarcoma | Other Name | |
Animal | human | Strain | |
Genus | Homo | Species | sapiens |
Sex | M | Age | 14 |
Identity | available | Tissue for Primary Cancer | sarcoma |
Case history | osteosarcoma | Metastasis | |
Tissue Metastasized | Genetics | ||
Life Span | infinite | Crisis PDL | |
Morphology | polygonal | Character | osteosarcoma |
Classify | tumor | Established by | Billiau, A. et al. |
Registered by | Igarashi,K. | Regulation for Distribution | |
Comment | Year | 1986 | |
Medium | Eagle's minimal essential medium with non-essential amino acids and 10% heat inactivated FBS | Methods for Passages | trypsin-EDTA |
Cell Number on Passage | Race | ||
CO2 Conc. | 5 % | Tissue Sampling | bone |
Tissue Type |
Detection of virus genome fragment by Real-time PCR | |||||||||
---|---|---|---|---|---|---|---|---|---|
Detected DNA Virus | not tested | Detected RNA Virus | tested | ||||||
HCV | - | HTLV-1 | - | ||||||
HIV-1 | - | HTLV-2 | - | ||||||
HIV-2 | - | HAV | - | ||||||
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||||||
Notes |
Reference | |
---|---|
Pubmed id:883813 | Human interferon: mass production in a newly established cell line, MG-63. Billiau A,Edy VG,Heremans H,Van Damme J,Desmyter J,Georgiades JA,De Somer P Antimicrob Agents Chemother. 1977 Jul;12(1):11-5 |
Images |
---|
Movies |
---|
LOT Information
Cell No. | IFO50108 | Cell Name | |
---|---|---|---|
LOT No. | 03182011 | Lot Specification | distribution |
Medium | Eagle's minimum essential medium with non-essential amino acids and 10% heat-inactivated fetal bovine serum (GIBCO Cat. # 10099). | Temperature | 37 C |
Cell Density at Seeding | approx. 3 x 10^4 cells/mL | Methods for Passages | 0.25% trypsin and 0.02% EDTA |
Doubling Time | approx. 1 day | Cell Number in Vial (cells/1ml) | 1.2 x 10^6 |
Viability at cell freezing (%) | 82.9 | Antibiotics Used | free |
Passage Number | P33 | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B), MD. |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | D5S818:11,12 D13S317:11 D7S820:10 D16S539:11,12 VWA:16,19 TH01:9.3 AM:X,Y TPOX:8,11 CSF1PO:10,12 |
|
Adhesion | Yes | Exoteric Gene | |
Medium for Freezing | 10% DMSO, 20% FBS - EMEM | CO2 Conc. | 5% |
Viability immediately after thawing (%) | Additional information |
Cell No. | IFO50108 | Cell Name | |
---|---|---|---|
LOT No. | 05262004 | Lot Specification | distribution |
Medium | Eagle's minimal essential medium with non-essential amino acids and 10% fetal bovine serum (FBS lot; GIBCO 3762782S) | Temperature | 37 C |
Cell Density at Seeding | 2-3 x 10^4 cells/ml | Methods for Passages | 0.25% trypsin and 0.02% EDTA |
Doubling Time | ca. 1 day | Cell Number in Vial (cells/1ml) | 7.4 x 10^5 |
Viability at cell freezing (%) | 86.4 | Antibiotics Used | free |
Passage Number | P32 | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B), MD, AST. |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | Yes | Exoteric Gene | |
Medium for Freezing | 10% DMSO, 20% FBS - culture medium | CO2 Conc. | 5% |
Viability immediately after thawing (%) | Additional information |
Cell No. | IFO50108 | Cell Name | MG-63 |
---|---|---|---|
LOT No. | 1032 | Lot Specification | distribution |
Medium | E.MEM with NEAA, 90% ; heat-inactivated FBS, 10% | Temperature | 37 C |
Cell Density at Seeding | Methods for Passages | trypsin-EDTA | |
Doubling Time | Cell Number in Vial (cells/1ml) | 6 x 10^5 | |
Viability at cell freezing (%) | 84 | Antibiotics Used | free |
Passage Number | P31 | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | NP, G6PD(type B), MD |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | Exoteric Gene | ||
Medium for Freezing | 10% DMSO, 20% serum (final conc.) - culture medium | CO2 Conc. | |
Viability immediately after thawing (%) | Additional information |
Cell No. | IFO50108 | Cell Name | MG-63 |
---|---|---|---|
LOT No. | 451 | Lot Specification | distribution |
Medium | E.MEM with NEAA, 90% ; heat-inactivated FBS, 10% | Temperature | 37 C |
Cell Density at Seeding | Methods for Passages | trypsin-EDTA | |
Doubling Time | Cell Number in Vial (cells/1ml) | 3 x 10^5 | |
Viability at cell freezing (%) | 78 | Antibiotics Used | free |
Passage Number | P32 | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | NP, G6PD(type B), MD, PepB |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | Exoteric Gene | ||
Medium for Freezing | 10% DMSO, 20% serum (final conc.) - culture medium | CO2 Conc. | |
Viability immediately after thawing (%) | Additional information |
Cell No. | IFO50108 | Cell Name | MG-63 |
---|---|---|---|
LOT No. | 05242018 | Lot Specification | distribution |
Medium | Eagle's minimum essential medium with non-essential amino acids and 10% heat-inactivated fetal bovine serum (FBS; Sigma Cat. # 172012) | Temperature | 37 C |
Cell Density at Seeding | 2.5 - 4.6 x 10^4 cells/mL | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
Doubling Time | approx. 28 hrs. | Cell Number in Vial (cells/1ml) | 1.9 x 10^6 |
Viability at cell freezing (%) | 87 | Antibiotics Used | free |
Passage Number | P32 | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | Yes | Exoteric Gene | |
Medium for Freezing | 10% DMSO, 20% FBS - culture medium | CO2 Conc. | 5% |
Viability immediately after thawing (%) | 87 | Additional information |